AI assistant
Evotec SE — Earnings Release 2015
Sep 15, 2015
151_rns_2015-09-15_c73685ad-afbc-44e6-9e41-fa38288134a1.html
Earnings Release
Open in viewerOpens in your device viewer
News Details
Corporate | 15 September 2015 07:19
Evotec AG increases its revenue guidance for 2015
DGAP-News: Evotec AG / Key word(s): Change in Forecast
2015-09-15 / 07:19
Hamburg, Germany - 15 September 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that it increases its
financial guidance for the current year. The Company now expects Group
revenues excluding milestones, upfronts and licences to increase by approx.
45% (previously: more than 35%) compared to last year (2014: EUR 73.4 m)
mainly as a result of Evotec's strong business performance of EVT Execute,
accelerated growth in the EVT Innovate business and a positive outlook for
the remainder of the year.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We're
delighted that our No. 1 drug discovery services continue to attract new
customers while satisfying the needs of our existing customers. Both
segments are performing very well at this stage."
All other elements of the Company's financial guidance as of 12 May 2015
are confirmed.
Evotec's Group EBITDA before changes in contingent considerations is
expected to be positive.
Evotec expects research and development (R&D) expenses to grow to EUR 15 m
- EUR 20 m in 2015.
Evotec will continue to invest in its technology platforms and capacities
in order to drive its long-term growth strategy. It is therefore planned
that up to EUR 10 m will be invested in further capacity increases and the
upgrade of Evotec's technological capabilities.
Liquidity is expected to be well in excess of EUR 100 m at 31 December
2015. This forecast excludes any potential cash outflow from M&A or similar
transactions.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
2015-09-15 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News Service
394521 2015-09-15